BrECADD regimen is superior in treating advanced HL: results from the HD21 trial
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2024-07-09
Просмотров: 578
Описание:
In this presentation, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the results of the HD21 trial (NCT02661503), which aimed to compare the superiority of progression-free survival (PFS) between the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) and BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) regimens in patients with advanced stage classical Hodgkin lymphoma (cHL). This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
